Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Beyer

Showing results (161-170 of 225) with videos related to

Pageof 23
Sort By:
Scientific Reports|November 2, 2022
Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndromeLars Heubner, Paul Leon Petrick, Andreas Güldner, et al.
Haematologica|March 9, 2019
Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based studyVincent Ten Cate, Anthonie W A Lensing, Jeffrey I Weitz, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|February 26, 2024
Risk Profiles and Treatment Patterns in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving or not Receiving Anticoagulation TherapyReinhold Kreutz, Gilbert Deray, Jürgen Floege, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 9, 2025
Indefinite anticoagulation with reduced-intensity direct oral anticoagulants in patients with splanchnic vein thrombosis. An international practice surveyAurélien Delluc, Marc Carrier, Mandy Lauw, et al.
British Journal of Clinical Pharmacology|April 5, 2014
Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registryJan Beyer-Westendorf, Vera Gelbricht, Kati Förster, et al.
Clinical and Translational Gastroenterology|August 16, 2018
Long-Term Outcome of Splanchnic Vein Thrombosis in CirrhosisMarco Senzolo, Nicoletta Riva, Francesco Dentali, et al.
Thrombosis Research|August 20, 2018
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patientsHugo Ten Cate, Anthonie W A Lensing, Jeffrey I Weitz, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2025
Anticoagulant Management After Emergency Surgery or Major Bleeding in Anticoagulated Patients-Results of the Prospective RADOA RegistryJana Last, Ingvild Birschmann, Simone Lindau, et al.
Thrombosis and Haemostasis|September 20, 2021
Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk ScoreMaria A de Winter, Jannick A N Dorresteijn, Walter Ageno, et al.
Neurological Research and Practice|May 1, 2022
Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registryWaltraud Pfeilschifter, Edelgard Lindhoff-Last, Ali Alhashim, et al.
Pageof 23

Showing results (161-170 of 225) with videos related to

Sort By:
Pageof 23
Scientific Reports|November 2, 2022
Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndromeLars Heubner, Paul Leon Petrick, Andreas Güldner, et al.
Haematologica|March 9, 2019
Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based studyVincent Ten Cate, Anthonie W A Lensing, Jeffrey I Weitz, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|February 26, 2024
Risk Profiles and Treatment Patterns in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving or not Receiving Anticoagulation TherapyReinhold Kreutz, Gilbert Deray, Jürgen Floege, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 9, 2025
Indefinite anticoagulation with reduced-intensity direct oral anticoagulants in patients with splanchnic vein thrombosis. An international practice surveyAurélien Delluc, Marc Carrier, Mandy Lauw, et al.
British Journal of Clinical Pharmacology|April 5, 2014
Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registryJan Beyer-Westendorf, Vera Gelbricht, Kati Förster, et al.
Clinical and Translational Gastroenterology|August 16, 2018
Long-Term Outcome of Splanchnic Vein Thrombosis in CirrhosisMarco Senzolo, Nicoletta Riva, Francesco Dentali, et al.
Thrombosis Research|August 20, 2018
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patientsHugo Ten Cate, Anthonie W A Lensing, Jeffrey I Weitz, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2025
Anticoagulant Management After Emergency Surgery or Major Bleeding in Anticoagulated Patients-Results of the Prospective RADOA RegistryJana Last, Ingvild Birschmann, Simone Lindau, et al.
Thrombosis and Haemostasis|September 20, 2021
Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk ScoreMaria A de Winter, Jannick A N Dorresteijn, Walter Ageno, et al.
Neurological Research and Practice|May 1, 2022
Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registryWaltraud Pfeilschifter, Edelgard Lindhoff-Last, Ali Alhashim, et al.
Pageof 23